Specifically, BRCA2 germline variants within the region c.6373–c.6492 exhibited a relative risk of 3.7 as compared with molecular changes outside this region [23], and pathogenic changes after the 3′ of c.7914 (prostate cancer cluster region or PrCCR) were significantly associated with an augmented risk of prostate cancer [24]. This evidence concerns the gene BRCA2 and prostate carcinoma.